Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Cutaneous Distribution, Systemic Screening, and Geospatial Risk in Sarcoidosis

Description

The transcript explains that sarcoidosis is defined not only by its appearance but also by where it occurs on the body and in the environment. Certain cutaneous patterns suggest higher systemic risk: facial involvement, especially lupus pernio, is strongly linked to chronic and treatment-refractory disease and often coexists with pulmonary and upper aerodigestive tract involvement; nail disease is a moderate signal; and scalp and mucosal involvement are emerging warning signs. Because skin sarcoidosis is frequently associated with extracutaneous disease, clinicians should screen beyond the skin, with chest imaging, ophthalmologic evaluation, and at minimum an EKG as baseline tests. The speaker emphasizes that dermatologists often identify previously unrecognized systemic disease, but cardiac screening is a major gap despite its importance because cardiac sarcoidosis can cause arrhythmia, conduction disease, heart failure, and sudden death. A practical approach is to ask about cardiac symptoms, obtain a baseline EKG, and refer to cardiology if symptoms or EKG abnormalities are present. The talk also highlights emerging geospatial research suggesting sarcoidosis risk may cluster in certain areas and correlate with environmental exposures such as oil release sites, hazardous waste locations, and chemical emissions, raising the possibility that geography and neighborhood factors may contribute to disease risk and disparities.

View more

Conclusions

Certain cutaneous sarcoidosis patterns—especially lupus pernio, and to a lesser extent nail, scalp, and mucosal involvement—should be treated as warning signs for greater systemic disease burden.
Because cutaneous sarcoidosis is frequently not skin-limited, a structured extracutaneous evaluation is warranted, with pulmonary disease being the most common associated internal manifestation.
Dermatologists often identify systemic sarcoidosis early, making skin-based diagnosis an important entry point for broader disease detection.
Routine baseline screening in cutaneous sarcoidosis should include chest imaging, ophthalmologic examination, and at minimum an ECG.
Cardiac sarcoidosis is uncommon but high-risk, so cardiac screening should not be skipped even when symptoms are absent.
A review of cardiac symptoms combined with a baseline ECG appears to be an effective first-line screening strategy, with abnormal ECG findings strongly associated with cardiac sarcoidosis in the reported cohort.
Geography and environmental exposure may contribute to sarcoidosis risk, as disease clusters appear to overlap with toxin exposure sites and neighborhood disadvantage.
Overall, sarcoidosis should be understood not only by morphology, but by the anatomic location of lesions, internal organ involvement, and possibly environmental context.

Spiteri et al. Br J Dermatol. 1985.
Imadojemu et al. Dermatol Clin. 2019.
Obijiofor et al. Int J Womens Dermatol. 2024.
Gaurav et al. Arch Dermatol Res. 2025.
Adapted from Imadojemu and Rosenbach. Dermatol Clin. 2019.
Villa-Ruiz et al. J Am Acad Dermatol. 2021.
Xia et al. JAMA Dermatol. 2025.
Ezeh et al. Dermatol Clin. 2023.
Asabor et al. Br J Dermatol. 2026.